| Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and … VG Athyros, K Tziomalos, TD Gossios, T Griva, P Anagnostis, K Kargiotis, ... The Lancet 376 (9756), 1916-1922, 2010 | 920 | 2010 |
| The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis P Anagnostis, VG Athyros, K Tziomalos, A Karagiannis, DP Mikhailidis The Journal of Clinical Endocrinology & Metabolism 94 (8), 2692-2701, 2009 | 839 | 2009 |
| Treatment with atorvastatin to the National Cholesterol Educational Program goal versus' usual'care in secondary coronary heart disease prevention VG Athyros, AA Papageorgiou, BR Mercouris, VV Athyrou, ... Current medical research and opinion 18 (4), 220-228, 2002 | 827 | 2002 |
| The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart … VG Athyros, DP Mikhailidis, AA Papageorgiou, AN Symeonidis, ... Journal of clinical pathology 57 (7), 728-734, 2004 | 513 | 2004 |
| Lifestyle recommendations for the prevention and management of metabolic syndrome: an international panel recommendation P Pérez-Martínez, DP Mikhailidis, VG Athyros, M Bullo, P Couture, ... Nutrition reviews 75 (5), 307-326, 2017 | 474 | 2017 |
| Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? SG Tsouli, EN Liberopoulos, DP Mikhailidis, VG Athyros, MS Elisaf Metabolism 55 (10), 1293-1301, 2006 | 385 | 2006 |
| Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia VG Athyros, AA Papageorgiou, VV Athyrou, DS Demitriadis, ... Diabetes care 25 (7), 1198-1202, 2002 | 350 | 2002 |
| Diabetes and lipid metabolism VG Athyros, M Doumas, KP Imprialos, K Stavropoulos, E Georgianou, ... Hormones 17, 61-67, 2018 | 346 | 2018 |
| Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study VG Athyros, DP Mikhailidis, TP Didangelos, OI Giouleme, ... Current medical research and opinion 22 (5), 873-883, 2006 | 342 | 2006 |
| “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses D P Mikhailidis, M Elisaf, M Rizzo, K Berneis, B Griffin, A Zambon, ... Current vascular pharmacology 9 (5), 533-571, 2011 | 333 | 2011 |
| Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary … VG Athyros, M Elisaf, AA Papageorgiou, AN Symeonidis, AN Pehlivanidis, ... American journal of kidney diseases 43 (4), 589-599, 2004 | 330 | 2004 |
| Diabetic nephropathy: new risk factors and improvements in diagnosis K Tziomalos, VG Athyros The review of diabetic studies: RDS 12 (1-2), 110, 2015 | 327 | 2015 |
| The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related … VG Athyros, TK Alexandrides, H Bilianou, E Cholongitas, M Doumas, ... Metabolism 71, 17-32, 2017 | 316 | 2017 |
| Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a … VG Athyros, DP Mikhailidis, EN Liberopoulos, AI Kakafika, A Karagiannis, ... Nephrology Dialysis Transplantation 22 (1), 118-127, 2007 | 293 | 2007 |
| Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY … KK Ray, HM Colhoun, M Szarek, M Baccara-Dinet, DL Bhatt, VA Bittner, ... The lancet Diabetes & endocrinology 7 (8), 618-628, 2019 | 288 | 2019 |
| The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions VG Athyros, ES Ganotakis, M Elisaf, DP Mikhailidis Current medical research and opinion 21 (8), 1157-1159, 2005 | 273 | 2005 |
| Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia HJ Milionis, AI Kakafika, SG Tsouli, VG Athyros, ET Bairaktari, ... American heart journal 148 (4), 635-640, 2004 | 249 | 2004 |
| The prevalence of the metabolic syndrome in Greece: the MetS‐Greece Multicentre Study VG Athyros, VI Bouloukos, AN Pehlivanidis, AA Papageorgiou, ... Diabetes, Obesity and Metabolism 7 (4), 397-405, 2005 | 240 | 2005 |
| Endothelial dysfunction in metabolic syndrome: prevalence, pathogenesis and management K Tziomalos, VG Athyros, A Karagiannis, DP Mikhailidis Nutrition, Metabolism and Cardiovascular Diseases 20 (2), 140-146, 2010 | 237 | 2010 |
| Atherosclerosis and osteoporosis: age-dependent degenerative processes or related entities? P Anagnostis, A Karagiannis, AI Kakafika, K Tziomalos, VG Athyros, ... Osteoporosis International 20, 197-207, 2009 | 223 | 2009 |
